实体瘤患者微量残留癌细胞检测的临床应用

手术切除原发瘤后，微量残留癌细胞(minimal residual cancer cell，MRCC)以及由此而产生的转移是所有治疗方法的靶标。由于以PCR为基础的检测系统灵敏度非常高，MRCC分子特征的鉴定将提供有关转移潜能、药靶可利用性、药物敏感性或治疗耐受性等方面的信息，弥补了原发瘤与通过影像技术等传统方法发现转移之间分析的缺陷，从而有助于治疗方案选择、治疗效果监测和预后预测，最终使患者从个体化医疗中获益。

Detection and clinical implication of minimal residual cancer cells in patients with solid tumors

After surgical removal of a primary tumor the minimal residual cancer cells (MRCC) and metastases derived thereof are the actual targets for all theraputic approaches. Due to the great sensitivity and PCR-based detection systems, the molecular characterization of MRCC can provide information about their metastatic potential, availability of drug targets, drug sensitivity and development of therapy resistance, which will close the analytical gap between primary disease and the detection of metastases by conventional methods such as imaging procedures, and this will help therapy selection, monitoring of the treatment effects and predicting of the prognosis. Patients will benefit from a individualized therapy in the end.